- NCIt
- C7711
Loading cancer entity…
Loading cancer entity…
Clinical trials
67 studies whose conditions map to this entity or one of its descendants. Status and phase are as posted on ClinicalTrials.gov. 50 studies per page.
Computedformula ci-trial-intel-v1 · interventional studies · entity + NCIt descendants · hover a figure for its formulaCompare cancersTerminated studies (11)
| NCT | Title | Status | Phase | Enrollment (n) | Sponsor | Countries | Last update | Source |
|---|---|---|---|---|---|---|---|---|
| NCT02379377 | 18F-FSPG PET in Imaging Patients With Liver Cancer Before Undergoing Surgery or Transplant | active not recruiting | Phase 1 | 110 | M.D. Anderson Cancer CenterOTHER | 1 | Jun 2, 2026 | clinicaltrials |
| NCT03211416 | Sorafenib Tosylate and Pembrolizumab in Treating Patients With Advanced or Metastatic Liver Cancer | completed | Phase 1 / Phase 2 | 37 | Roswell Park Cancer InstituteOTHER | 1 | Feb 5, 2026 | clinicaltrials |
| NCT04497038 | Cabozantinib in Patients With Advanced Hepatocellular Carcinoma With Child Pugh Class B Cirrhosis After First-Line Therapy | terminated | Phase 1 / Phase 2 | 3 | University of Michigan Rogel Cancer CenterOTHER | 1 | Aug 6, 2024 | clinicaltrials |
| NCT02024087 | Study of Dalantercept and Sorafenib in Patients With Advanced Hepatocellular Carcinoma | completed | Phase 1 / Phase 2 | 21 | Acceleron Pharma, Inc., a wholly-owned subsidiary of Merck & Co., Inc., Rahway, NJ USAINDUSTRY | 1 | Sep 26, 2022 | clinicaltrials |
| NCT01666756 | Chinese Herbal Formulation PHY906 and Sorafenib Tosylate in Treating Patients With Advanced Liver Cancer | completed | Phase 1 | 18 | City of Hope Medical CenterOTHER | 1 | Jan 27, 2021 | clinicaltrials |
| NCT01835223 | Tivozanib in Treating Patients With Liver Cancer That Is Metastatic or Cannot Be Removed by Surgery | completed | Phase 1 / Phase 2 | 33 | Roswell Park Cancer InstituteOTHER | 1 | Oct 28, 2020 | clinicaltrials |
| NCT00321594 | Belinostat in Treating Patients With Liver Cancer That Cannot Be Removed By Surgery | completed | Phase 1 / Phase 2 | 54 | National Cancer Institute (NCI)NIH | 2 | Nov 6, 2017 | clinicaltrials |
| NCT01839604 | A Phase I/Ib Study of AZD9150 (ISIS-STAT3Rx) in Patients With Advanced/Metastatic Hepatocellular Carcinoma | completed | Phase 1 | 58 | AstraZenecaINDUSTRY | 4 | Mar 6, 2017 | clinicaltrials |
| NCT01008566 | Cixutumumab and Sorafenib Tosylate in Treating Patients With Advanced Liver Cancer | completed | Phase 1 | 21 | National Cancer Institute (NCI)NIH | 1 | May 12, 2016 | clinicaltrials |
| NCT02578602 | MRI With Gadoxetate Disodium in Measuring Tumors in Patients With Liver Cancer | completed | Phase 1 | 26 | University of Southern CaliforniaOTHER | 1 | Oct 19, 2015 | clinicaltrials |
| NCT00608361 | Dasatinib in Treating Patients With Solid Tumors or Lymphomas That Are Metastatic or Cannot Be Removed By Surgery | completed | Phase 1 | 80 | National Cancer Institute (NCI)NIH | 1 | Jul 2, 2015 | clinicaltrials |
| NCT00844168 | Sorafenib Tosylate in Treating Patients With Liver Cancer Who Have Undergone a Liver Transplant | completed | Phase 1 | 4 | University of WashingtonOTHER | 1 | Mar 27, 2015 | clinicaltrials |
| NCT00028496 | Vaccine Therapy With or Without Sargramostim in Treating Patients With Advanced or Metastatic Cancer | completed | Phase 1 | 48 | National Cancer Institute (NCI)NIH | 1 | Jan 25, 2013 | clinicaltrials |
| NCT00047346 | Erlotinib in Treating Patients With Unresectable Liver Cancer and Liver Dysfunction | completed | Phase 1 | 24 | National Cancer Institute (NCI)NIH | 1 | Jan 23, 2013 | clinicaltrials |
| NCT00030498 | Erlotinib in Treating Patients With Solid Tumors and Liver or Kidney Dysfunction | completed | Phase 1 | 75 | National Cancer Institute (NCI)NIH | 1 | Jan 16, 2013 | clinicaltrials |
Data updated 22 days agoSource updated Jun 2, 2026source: clinicaltrials